AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23848989 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly (QW/QW)
Number of subjects: 270
Study 23848989 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly (BIW/QW)
Number of subjects: 270
Study 23848989 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (both dosing regimens)
Number of subjects: 270
Study 23848989 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 270
Study 22921386 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone SMS intervention
Number of subjects: 258
Study 22921386 — intervention group
Group type: COMPARATOR
Intervention: Standard follow‐up appointments (Control)
Number of subjects: 258
Study 20557313 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg aspirin per day for 6 months
Number of subjects: 106
Study 20557313 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg aspirin per day for 6 months
Number of subjects: 106
Study 20557313 — intervention group
Group type: COMPARATOR
Intervention: Both doses of aspirin
Number of subjects: 106
Study 18596733 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose epoetin-alpha
Number of subjects: 0
Study 18596733 — intervention group
Group type: COMPARATOR
Intervention: Low-dose epoetin-alpha
Number of subjects: 0
Study 18596733 — intervention group
Group type: EXPERIMENTAL
Intervention: High hemoglobin arm
Number of subjects: 0
Study 16059627 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal spray salmon calcitonin (CT‐NS)
Number of subjects: 91
Study 16059627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 12870055 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (2 mg/day)
Number of subjects: 34
Study 12870055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 10235588 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth plus metronidazole and amoxicillin (group A)
Number of subjects: 126
Study 10235588 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole plus amoxicillin (group B)
Number of subjects: 126
Study 10235588 — intervention group
Group type: COMPARATOR
Intervention: H. pylori-positive patients post-treatment
Number of subjects: 126
Study 8638836 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 10
Study 8638836 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 10
Study 1472937 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose alpha 2B interferon (9 mU/week) in combination with oral chemotherapy
Number of subjects: 0
Study 1472937 — intervention group
Group type: COMPARATOR
Intervention: Oral chemotherapy only (control group)
Number of subjects: 0
Study 6329567 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha
Number of subjects: 32
Study 6329567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 6329567 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone and azathioprine
Number of subjects: 32
Study 6329567 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone, azathioprine, and OKT3 antibody
Number of subjects: 32
Study 31048448 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced stroke self-management programme (COMBO-KEY) plus usual care
Number of subjects: 0
Study 31048448 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 0
Study 29288764 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus tivantinib (150 mg once daily and 360 mg twice daily)
Number of subjects: 109
Study 29288764 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib plus placebo
Number of subjects: 109
Study 29288764 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus tivantinib
Number of subjects: 109
Study 27567363 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (80mg daily until labor, max 18 days)
Number of subjects: 50
Study 27567363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 27567363 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 50
Study 25381774 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine for paediatric retrieval consultations
Number of subjects: 160
Study 25381774 — intervention group
Group type: COMPARATOR
Intervention: Telephone for paediatric retrieval consultations
Number of subjects: 160
Study 25381774 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine
Number of subjects: 160
Study 23111148 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical-grade honey applied in addition to standard CVC-site dressing and disinfection with 0.5% chlorhexidine in 70% alcohol.
Number of subjects: 235
Study 23111148 — intervention group
Group type: COMPARATOR
Intervention: Standard care (CVC-site dressing and disinfection with 0.5% chlorhexidine in 70% alcohol).
Number of subjects: 235
Study 23111148 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical-grade honey
Number of subjects: 235
Study 23111148 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 235
Study 19937752 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspnea-related anxiety and distress rated on the Modified Borg Scale after a 6-minute walk and an incremental treadmill test
Number of subjects: 103
Study 19937752 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspnea-related anxiety and distress
Number of subjects: 103
Study 17927634 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing salivary substitutes
Number of subjects: 20
Study 17927634 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 20
Study 15843333 — intervention group
Group type: EXPERIMENTAL
Intervention: School-wide curriculum-based programs presented to students
Number of subjects: 210
Study 15843333 — intervention group
Group type: EXPERIMENTAL
Intervention: In-service presentations to school staff
Number of subjects: 210
Study 15843333 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report screening programs for students
Number of subjects: 210
Study 11994701 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg twice daily)
Number of subjects: 16
Study 11994701 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast (80 mg twice daily)
Number of subjects: 16
Study 11994701 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of loratadine and zafirlukast
Number of subjects: 16
Study 11994701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11994701 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast
Number of subjects: 16
Study 11994701 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of zafirlukast and loratadine
Number of subjects: 16
Study 11994701 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine alone
Number of subjects: 16
Study 11994701 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast alone vs combination with loratadine
Number of subjects: 16
Study 9708136 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational and behavioral intervention
Number of subjects: 108
Study 9708136 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 108
Study 7843449 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-blocker (bunazosin) 2 mg/d for 6 months
Number of subjects: 34
Study 7843449 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two tablets per day for 6 months)
Number of subjects: 34
Study 1903599 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral glutamine infusion at graded rates (0 to 126 mmol/h)
Number of subjects: 10
Study 1903599 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral glutamine infusion at 46.8 mmol/h
Number of subjects: 10
Study 1903599 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral glutamine infusion
Number of subjects: 10
Study 7327784 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomerleau and Pomerleau's 1977 manual
Number of subjects: 40
Study 7327784 — intervention group
Group type: EXPERIMENTAL
Intervention: Danaher and Lichtenstein's 1978 manual
Number of subjects: 40
Study 7327784 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 40
Study 30597688 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine 0.1, 0.2, 0.5, 1.0 mg/kg
Number of subjects: 99
Study 30597688 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 0.045 mg/kg (active placebo)
Number of subjects: 99
Study 28768921 — intervention group
Group type: EXPERIMENTAL
Intervention: Evacetrapib 130 mg daily for 12 weeks
Number of subjects: 149
Study 28768921 — intervention group
Group type: COMPARATOR
Intervention: Placebo/atorvastatin
Number of subjects: 149
Study 26105582 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (160 mg/day) for 8 weeks in obese patients without T2DM
Number of subjects: 44
Study 26105582 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (160 mg/day) for 8 weeks in obese patients with T2DM
Number of subjects: 44
Study 26105582 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (160 mg/day) and pioglitazone (15 mg/day) combination for 8 weeks in obese patients with T2DM
Number of subjects: 44
Study 24389932 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hyperthermia therapy (body core temperature 38.6 °C) combined with multimodal inpatient rehabilitation
Number of subjects: 88
Study 24389932 — intervention group
Group type: COMPARATOR
Intervention: Multimodal inpatient rehabilitation alone (control group)
Number of subjects: 88
Study 22464343 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid genotyping group (CYP2C19*2 carriers treated with 10 mg prasugrel daily)
Number of subjects: 200
Study 22464343 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment group (CYP2C19*2 carriers treated with 75 mg clopidogrel daily)
Number of subjects: 200
Study 20703198 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 10-60 mg/day for 12 weeks
Number of subjects: 262
Study 20703198 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine continuation
Number of subjects: 262
Study 20703198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study 17546266 — intervention group
Group type: EXPERIMENTAL
Intervention: DLC coated stent (Phytis)
Number of subjects: 180
Study 17546266 — intervention group
Group type: COMPARATOR
Intervention: Uncoated stent (Penta)
Number of subjects: 180
Study 15777603 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol HFA MDI 50 microg twice daily
Number of subjects: 0
Study 15777603 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol CFC MDI 50 microg twice daily
Number of subjects: 0
Study 15777603 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol HFA MDI
Number of subjects: 0
Study 15777603 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol CFC MDI
Number of subjects: 0
Study 12482334 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolization therapy with polyvinyl alcohol foam (Ivalon) as a single agent
Number of subjects: 50
Study 12482334 — intervention group
Group type: COMPARATOR
Intervention: Chemoembolization using polyvinyl alcohol foam mixed with 750 mg/m2 of 5‐fluorouracil and 9 million units of interferon
Number of subjects: 50
Study 12482334 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 50
Study 12482334 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with extrahepatic disease
Number of subjects: 50
Study 12482334 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with liver-only metastases
Number of subjects: 50
Study 9588435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan injection (6 mg)
Number of subjects: 135
Study 9588435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 8575241 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide treatment (2.5 mg)
Number of subjects: 5665
Study 8575241 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 5665
Study 2243350 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg/70 kg i.m.) at 6 hr post-morphine (18 mg/70 kg or 30 mg/70 kg)
Number of subjects: 6
Study 2243350 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg/70 kg i.m.) at 12 hr post-morphine (18 mg/70 kg or 30 mg/70 kg)
Number of subjects: 6
Study 2243350 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg/70 kg i.m.) at 24 hr post-morphine (18 mg/70 kg or 30 mg/70 kg)
Number of subjects: 6
Study 2243350 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg/70 kg i.m.) at 36 hr post-morphine (18 mg/70 kg or 30 mg/70 kg)
Number of subjects: 6
Study 2243350 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg/70 kg i.m.) at 48 hr post-morphine (18 mg/70 kg or 30 mg/70 kg)
Number of subjects: 6
Study 2243350 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg/70 kg i.m.) at 60 hr post-morphine (18 mg/70 kg or 30 mg/70 kg)
Number of subjects: 6
Study 2243350 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg/70 kg i.m.) at 72 hr post-morphine (18 mg/70 kg or 30 mg/70 kg)
Number of subjects: 6
Study 333556 — intervention group
Group type: EXPERIMENTAL
Intervention: sulphasomidine
Number of subjects: 28
Study 333556 — intervention group
Group type: EXPERIMENTAL
Intervention: sulphalene
Number of subjects: 28
Study 31277301 — intervention group
Group type: EXPERIMENTAL
Intervention: GEE extract 1000 mg/day
Number of subjects: 78
Study 31277301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 27753794 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepavax-Gene TF vaccine
Number of subjects: 0
Study 27753794 — intervention group
Group type: COMPARATOR
Intervention: Engerix-B vaccine
Number of subjects: 0
Study 27753794 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 0
Study 25659228 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning stickers for household salt containers
Number of subjects: 150
Study 25659228 — intervention group
Group type: COMPARATOR
Intervention: Leaflet about the harmful effects of excessive salt intake (control)
Number of subjects: 150
Study 23585310 — intervention group
Group type: EXPERIMENTAL
Intervention: No Test Atorvastatin 80 mg/day (A80)
Number of subjects: 0
Study 23585310 — intervention group
Group type: EXPERIMENTAL
Intervention: KIF6 Testing
Number of subjects: 0
Study 23585310 — intervention group
Group type: EXPERIMENTAL
Intervention: No Test Pravastatin 40 mg/day (P40)
Number of subjects: 0
Study 23585310 — intervention group
Group type: COMPARATOR
Intervention: No Test A80
Number of subjects: 0
Study 22569014 — intervention group
Group type: COMPARATOR
Intervention: 1 mg of epinephrine with a nasal pack soaked in 20 mL of saline for 10 minutes before surgery
Number of subjects: 30
Study 22569014 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of epinephrine with a nasal pack soaked in 20 mL of saline for 10 minutes before surgery
Number of subjects: 30
Study 19019052 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral occipital nerve blocks
Number of subjects: 50
Study 19019052 — intervention group
Group type: COMPARATOR
Intervention: Conventional expectant therapy (adequate hydration, complete bed rest, and analgesics)
Number of subjects: 50
Study 17710964 — intervention group
Group type: EXPERIMENTAL
Intervention: Pueraria mirifica, oral 50 and 100 mg capsule, once daily for six months
Number of subjects: 10
Study 15186874 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture-specific diabetes care intervention
Number of subjects: 101
Study 11513444 — intervention group
Group type: COMPARATOR
Intervention: Active can anode
Number of subjects: 68
Study 11513444 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-finger array lead
Number of subjects: 68
Study 11513444 — intervention group
Group type: EXPERIMENTAL
Intervention: Omitting the middle finger of the array lead
Number of subjects: 68
Study 11513444 — intervention group
Group type: COMPARATOR
Intervention: Active can device with two-finger array lead
Number of subjects: 68
Study 9041281 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin-Releasing Hormone (TRH) 200 microg
Number of subjects: 1022
Study 8261468 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg furafylline
Number of subjects: 6
Study 8261468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2445932 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 119
Study 2445932 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin-C plus Cisplatin (MC)
Number of subjects: 119
Study 2445932 — intervention group
Group type: EXPERIMENTAL
Intervention: MVB plus Cisplatin (MVBC)
Number of subjects: 119
Study 31604440 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel personalized TKR design (Persona CR, Zimmer, Warsaw, IN, USA)
Number of subjects: 240
Study 31604440 — intervention group
Group type: COMPARATOR
Intervention: Conventional TKR design (PFC CR, DePuy, Warsaw, IN, USA)
Number of subjects: 240
Study 31604440 — intervention group
Group type: COMPARATOR
Intervention: Conventional TKR design (Nexgen CR, Zimmer, Warsaw, IN, USA)
Number of subjects: 240
Study 29890724 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose 5 g
Number of subjects: 27
Study 29890724 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose 10 g
Number of subjects: 27
Study 29890724 — intervention group
Group type: EXPERIMENTAL
Intervention: Allulose 5 g
Number of subjects: 27
Study 29890724 — intervention group
Group type: EXPERIMENTAL
Intervention: Allulose 10 g
Number of subjects: 27
Study 29890724 — intervention group
Group type: COMPARATOR
Intervention: Control (0 g)
Number of subjects: 27
Study 26883282 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone conference call
Number of subjects: 70
Study 26883282 — intervention group
Group type: COMPARATOR
Intervention: Social media platform
Number of subjects: 70
Study 23984673 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg/day
Number of subjects: 426
Study 23984673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 426
Study 22810946 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonopen XL measurement of IOP through low-power lotrafilcon B lenses
Number of subjects: 78
Study 22810946 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonopen XL measurement of IOP through high-power lotrafilcon B lenses
Number of subjects: 78
Study 22810946 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonopen XL measurement of IOP through low-power galyfilcon A lenses
Number of subjects: 78
Study 22810946 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonopen XL measurement of IOP through high-power galyfilcon A lenses
Number of subjects: 78
Study 22810946 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonopen XL measurement of IOP through senofilcon A lenses
Number of subjects: 78
Study 20979671 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutter mucus-clearance device
Number of subjects: 60
Study 20979671 — intervention group
Group type: COMPARATOR
Intervention: Control (routine healthcare)
Number of subjects: 60
Study 19018688 — intervention group
Group type: EXPERIMENTAL
Intervention: Manidipine 20 mg
Number of subjects: 91
Study 19018688 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg
Number of subjects: 91
Study 16085605 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip replacement
Number of subjects: 102
Study 16085605 — intervention group
Group type: COMPARATOR
Intervention: Internal fixation
Number of subjects: 102
Study 12046885 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound ablation (Group 1)
Number of subjects: 4
Study 12046885 — intervention group
Group type: COMPARATOR
Intervention: Standard cross‐cylinder technique (Group 2)
Number of subjects: 4
Study 10073834 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ventricular tachyarrhythmias (VT)
Number of subjects: 0
Study 10073834 — intervention group
Group type: COMPARATOR
Intervention: Patients without ventricular tachyarrhythmias (VT)
Number of subjects: 0
Study 7741574 — intervention group
Group type: EXPERIMENTAL
Intervention: Spacer
Number of subjects: 60
Study 7741574 — intervention group
Group type: COMPARATOR
Intervention: Nebuliser
Number of subjects: 60
Study 2147609 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (K)
Number of subjects: 32
Study 2147609 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate (SCG)
Number of subjects: 32
Study 6989377 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibate
Number of subjects: 95
Study 6989377 — intervention group
Group type: COMPARATOR
Intervention: Diet
Number of subjects: 95
Study 6989377 — intervention group
Group type: EXPERIMENTAL
Intervention: Niceritrol
Number of subjects: 95
Study 31965682 — intervention group
Group type: EXPERIMENTAL
Intervention: Subepidermal moisture (SEM) biocapacitance measurement
Number of subjects: 182
Study 31965682 — intervention group
Group type: COMPARATOR
Intervention: Standard of care clinical interventions
Number of subjects: 182
Study 31532805 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping
Number of subjects: 187
Study 31532805 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 187
Study 31532805 — intervention group
Group type: COMPARATOR
Intervention: Insight, medication adherence, addiction
Number of subjects: 187
Study 27993816 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (5 mg/kg/week for 1 year)
Number of subjects: 2591
Study 27993816 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 2591
Study 27993816 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with chemotherapy
Number of subjects: 2591
Study 27993816 — intervention group
Group type: COMPARATOR
Intervention: Both treatment arms
Number of subjects: 2591
Study 25761742 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum uric acid levels
Number of subjects: 93
Study 23625191 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab
Number of subjects: 0
Study 23625191 — intervention group
Group type: COMPARATOR
Intervention: Best Supportive Care (BSC)
Number of subjects: 0
Study 21276883 — intervention group
Group type: EXPERIMENTAL
Intervention: LPV/r (lopinavir/ritonavir) monotherapy
Number of subjects: 136
Study 21276883 — intervention group
Group type: COMPARATOR
Intervention: LPV/r+ZDV+3TC (lopinavir/ritonavir with zidovudine and lamivudine)
Number of subjects: 136